TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06177301
Drug: Tislelizumab combined with GP
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles.
Study: NCT00511771
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tegaserod maleate
Study: NCT01230762
Drug: dapoxetine
Normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
Study: NCT05841056
Drug: Amiodarone Hydrochloride 200 MG
Normalized name: amiodarone hydrochloride 200 MG
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg daily for 4 weeks
Study: NCT04988555
Drug: azoles
Normalized name: ItraconazolesTablets
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posaconazole, Voriconazole, or Fluconazole
Study: NCT04988555
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax orally
Study: NCT04988555
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gilteritinib orally
Study: NCT04988555
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine orally
Study: NCT04569695
Drug: JNJ-70033093
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
Study: NCT06116916
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study: NCT06571149
Drug: Tenecteplase or Alteplase
Normalized name: Tenecteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to intravenous thrombolysis (IVT) treatment will receive intravenous Tenecteplase or Alteplase.
Study: NCT05413551
Drug: Low-dose isoniazid
Normalized name: ethinyl estradiol
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
Study: NCT05413551
Drug: Standard dose of isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/kg oral tablet (up to 900 mg)
Study: NCT05413551
Drug: High-dose isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
Study: NCT05139238
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous labetalol, a short acting ant-hypertensive
Study: NCT05139238
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine, a short acting ant-hypertensive
Study: NCT05896839
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05896839
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06317649
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT06077669
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of methylphenidate (5mg or 10 mg)
Study: NCT06317649
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06317649
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05538897
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05538897
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06560762
Drug: STM01
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neonatal mesenchymal stem cells (nMSCs),
Study: NCT05891834
Drug: INV-202
Normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet, once daily, oral
Study: NCT05848453
Drug: BAP5191
Normalized name: BAP5191
DrugBank: BAP5191 (DB18021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04906395
Drug: TOL2506
DrugBank: TOL2 (DB17918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
Study: NCT04906395
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg once daily or 10 mg 2 times daily - either tablet or solution
Study: NCT04906395
Drug: Letrozole Tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 2.5 mg tablet taken orally once daily
Study: NCT04906395
Drug: Anastrozole Tablets
Normalized name: Anastrozole Tablets
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 1 mg tablet taken orally once daily
Study: NCT04906395
Drug: Exemestane Tablets
Normalized name: Exemestane Tablets
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 25 mg tablet taken orally once daily
Study: NCT05370547
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
Study: NCT04001998
Drug: BLD-2660
Normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to active product
Study: NCT06420089
Drug: Senza5 CART5
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
Study: NCT05759481
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is administered starting at surgery induction and ending at skin closure
Study: NCT04988386
Drug: Acoramidis (AG10)
Normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoramidis (AG10) twice daily
Study: NCT05766384
Drug: Hyperpolarized Xe129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
Study: NCT04882072
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Study: NCT05443724
Drug: CVL-231 30 mg
Normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05338775
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered as a subcutaneous (SC) injection.
Study: NCT05338775
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered as a SC injection.
Study: NCT05338775
Drug: PD-1 Inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PD-1 inhibitor will be administered as an intravenous injection.
Study: NCT05632809
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT06531811
Drug: AZD8630 (test formulation) via test inhaler
Normalized name: tuberculin skin test; unspecified formulation
DrugBank: AZD8630 (DB19397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD8630 via test inhaler.
Study: NCT06531811
Drug: AZD8630 (reference formulation) via Monodose inhaler
Normalized name: AZD8630
DrugBank: AZD8630 (DB19397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD8630 via Monodose inhaler.
Study: NCT04750577
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet
Study: NCT05957302
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
Study: NCT06340360
Drug: Rezpegaldesleukin
Normalized name: Rezpegaldesleukin
DrugBank: Rezpegaldesleukin (DB18992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT06065462
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by vein (IV)
Study: NCT06065462
Drug: LB-100
Normalized name: LB-100
DrugBank: LB-100 (DB15412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIven by vein (IV)
Study: NCT06140576
Drug: Sindilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sindilimab, 200mg, Intravenous，every three weeks
Study: NCT06140576
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
Study: NCT06140576
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 8mg, 12mg, 16mg everyday
Study: NCT05388669
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib tablets will be administered orally.
Study: NCT05388669
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amivantamab injection will be administered subcutaneously by manual injection.
Study: NCT05388669
Drug: Amivantamab Intravenous
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered by IV infusion.
Study: NCT05213624
Drug: BI 764198
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT04963725
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
Study: NCT06116890
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study: NCT05204355
Drug: Hyperpolarized Xe129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
Study: NCT04844814
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
Normalized name: ANAKINRA 100MG/0.67ML INJ SYRINGE
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg/d subcutaneous injection
Study: NCT04844814
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 30 mg/d
Study: NCT04844814
Drug: Placebo of Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of Prednisone
Study: NCT04844814
Drug: Placebo of Anakinra
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo of Anakinra
Study: NCT06073821
Drug: Sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06073821
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT06073821
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT06073821
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT06179888
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06647498
Drug: Remternetug
Normalized name: Remternetug
DrugBank: Remternetug (DB18994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously every 12 weeks
Study: NCT06531824
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517
Study: NCT06531824
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin
Study: NCT05767034
Drug: Secukinumab 300 mg
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Study: NCT05767034
Drug: Secukinumab 150 mg
Normalized name: secukinumab 150 MG/ML
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Study: NCT05834348
Drug: lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As provided in real world practice
Study: NCT05834348
Drug: brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As provided in real world practice
Study: NCT05834348
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As provided in real world practice
Study: NCT05834348
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As provided in real world practice
Study: NCT05834348
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As provided in real world practice
Study: NCT05834348
Drug: dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05834348
Drug: entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As provided in real world practice
Study: NCT05364554
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT06731335
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSILOCYBIN (PEX010) 25 mg PO single dose
Study: NCT05742438
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous intravenous infusion of lidocaine
Study: NCT05742438
Drug: Dexmedetomidine IV
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous intravenous infusion of dexmedetomidine
Study: NCT05742438
Drug: intrathecal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal morphine injection
Study: NCT06309485
Drug: Sorafenib 400 mg PO, BID continuously
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study: NCT06309485
Drug: Sorafenib 400 mg PO, BID
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study: NCT05804227
Drug: Ulixertinib
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
Study: NCT05717062
Drug: Varespladib intravenous form
Normalized name: Varespladib
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
Study: NCT05717062
Drug: varespladib-methyl- oral form
Normalized name: methylal
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
Study: NCT04895696
Drug: Afimetoran
Normalized name: Afimetoran
DrugBank: Afimetoran (DB16580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06559137
Drug: Ropivacaine 0.2% Injectable Solution
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
Study: NCT06559215
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive Exparel intraoperatively via local infiltration. The dosage will be dependent on patient weight.
Study: NCT05600894
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04882033
Drug: Concurrent chemoradiotherapy plus anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy.
Study: NCT05367271
Drug: Botulinum Toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
Study: NCT05367271
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
Study: NCT05197062
Drug: 14C-aticaprant
Normalized name: urea [14C]
DrugBank: Aticaprant (DB12341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-aticaprant will be administered orally as capsule on Day 1.
Study: NCT06450873
Drug: Coriolus Versicolor Extract
Normalized name: Iris versicolor root extract
DrugBank: Trametes versicolor fruiting body (DB14287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement Given PO
Study: NCT05288777
Drug: T-DM1
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.